ReviewHealthcare (Basel, Switzerland)2022
Antihypertensive Medications for Severe Hypertension in Pregnancy: A Systematic Review and Meta-Analysis.
Review in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Efficacy and Safety of Nifedipine Compared to Intravenous Hydralazine for Severe Hypertensive Disorders in Pregnancy: A Systematic Review and Meta-Analysis of Randmomized Controlled Trials.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Pooled it
- Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- The pathophysiology of pre-eclampsia.Nature reviews. Nephrology · 2026Review
- Labetalol, Nifedipine, and Methyldopa for the Management of Hypertensive Disorders in Pregnancy in Iran: A Cost-Effectiveness Analysis.Health science reports · 2026Article
- Updates in the 2025 AHA/ACC Hypertension Guideline.Current hypertension reports · 2026Review
- Eplerenone lowers maternal blood pressure in a model of leptin-induced preeclampsia, but decreases fetal growth when administered mid-, but not late-, gestation.American journal of physiology. Heart and circulatory physiology · 2026Article
- Efficacy and safety of labetalol vs. Hydralazine in pregnant women with severe hypertension.Pakistan journal of medical sciences · 2026Article
- Hypertension in Pregnancy and Postpartum: Current Standards and Opportunities to Improve Care.Circulation · 2025Review
- Antihypertensive, Anti-Inflammatory, and Antiangiogenic In Silico Activity of Lactoferrin-Derived Peptides of Equine Milk Hydrolysate.Biomedicines · 2024Article
- Hypertensive Disorders of Pregnancy: Diagnosis, Management and Timing of Birth.Balkan medical journal · 2024Review
- Pharmacotherapeutic options for the treatment of hypertension in pregnancy.Expert opinion on pharmacotherapy · 2024Review
- Diagnosis and Treatment of Eclampsia.Journal of cardiovascular development and disease · 2024Review
- Features and Comparative Characteristics of Fucosylated Glycans Expression in Endothelial Glycocalyx of Placental Terminal Villi in Patients with Preeclampsia Treated with Different Antihypertensive Regimens.International journal of molecular sciences · 2023Article
- Risk Factors of Adverse Maternal Outcome among SARS-CoV-2 Infected Critically Ill Pregnant Women in Serbia.Journal of clinical medicine · 2023Article
- The Management of Hypertensive Emergencies-Is There a "Magical" Prescription for All?Journal of clinical medicine · 2022Review
- Exploring Preeclampsia: A Comprehensive Overview.Discoveries (Craiova, Romania)Review
- Effects of Auriculotherapy on Gestational Hypertension: Randomized Controlled Trial Study.Iranian journal of nursing and midwifery researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundHypertension in pregnancy causes significant maternal and fetal mortality and morbidity. A comprehensive assessment of the effectiveness of antihypertensive drugs for severe hypertension during pregnancy is needed to make informed decisions in clinical practice. This systematic review aimed to assess the efficacy and safety of antihypertensive drugs in severe hypertension during pregnancy.
methodsA systematic review using the electronic databases MEDLINE (PubMed) and Cochrane Library was performed until August 2021. The risk-of-bias 2 tool was used to assess the risk-of-bias in each study included. Meta-analysis was conducted to assess heterogeneity and to estimate the pooled effects size.
resultsSeventeen studies fulfilled the inclusion criteria and 11 were included in the meta-analysis. Nifedipine was estimated to have a low risk in persistent hypertension compared to hydralazine (RR 0.40, 95% CI 0.23-0.71) and labetalol (RR 0.71, 95% CI 0.52-0.97). Dihydralazine was associated with a lower risk of persistent hypertension than ketanserin (RR 5.26, 95% CI 2.01-13.76). No difference was found in the risk of maternal hypotension, maternal and fetal outcomes, and adverse effects between antihypertensive drugs, except for dihydralazine, which was associated with more adverse effects than ketanserin.
conclusionsSeveral drugs can be used to treat severe hypertension in pregnancy, including oral/sublingual nifedipine, IV/oral labetalol, oral methyldopa, IV hydralazine, IV dihydralazine, IV ketanserin, IV nicardipine, IV urapidil, and IV diazoxide. In addition, nifedipine may be preferred as the first-line agent. There was no difference in the risk of maternal hypotension, maternal and fetal outcomes, and adverse effects between the drugs, except for adverse effects in IV dihydralazine and IV ketanserin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.